Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis

Abstract

In the presence of mild decompensation (Child-Pugh ≥6), SVR12 rates with protease inhibitor triple therapy are significantly reduced and adverse events increased. Thus, treatment with protease inhibitor triple therapy, if judged as necessary, should be undertaken with close monitoring and awareness of the significant risks.